{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-026322","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.898656+00:00","generated_at":"2026-05-24T02:06:19.291287+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OS Therapies reports FY2024 net operating loss of $10.9M; cash runway into 2026","bullets":["Net operating loss $10.886M in 2024 vs $7.916M in 2023, driven by IPO costs.","Net loss per share $0.88 on 12.38M shares vs $1.46 on 5.43M shares in 2023.","Cash on hand expected to last into 2026 due to reduced burn rate starting Q2 2025.","Full Phase 2b OST-HER2 data to be presented June 2025; BLA submission targeted for year-end 2025.","Plans to divest anticipated Priority Review Voucher (PRV) from potential BLA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-026322","json":"https://secwatch.observer/filing/0001213900-25-026322.json","markdown":"https://secwatch.observer/filing/0001213900-25-026322.md","text":"https://secwatch.observer/filing/0001213900-25-026322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/0001213900-25-026322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/ea0236436-8k_ostherapi.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:06:19.291287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}